Phase 2 N=34 Neoadjuvant and Adjuvant Checkpoint Blockade
Cutaneous Melanoma · Mucosal Melanoma · Ocular Melanoma
Primary: Arm C: Number of Participants With the Pathologic Response Rate — 0; 0; 34 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=62 Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects
Hyperkalaemia
Primary: Maximum Observed Concentration (Cmax) — 27140; 19350; 593.6; 608.1 Picogram/milliliter (pg/ml)
Phase 4 N=154 Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study
Disease Due to BK Polyomavirus · Kidney Transplant Infection
Primary: Occurrence of BK Viruria — 22; 26 Participants
N/A N=186 Molecular-Guided Therapy for Childhood Cancer
Neuroblastoma · Medulloblastoma · Glioma
Primary: Days to Treatment Will be Used in Order to Determine Feasibility of Using Tumor Samples to Assess Genomic Sequencing Using Predictive Modeling to Make Real-time…
Phase 2 N=40 Oxytocin and Social Cognitive Skills Groups
Autism Spectrum Disorder
Primary: Change From Baseline in Social Behavior Impairment (SBI) Composite — 0.12; -0.14; -0.26; -0.16 z-score — p=0.037
N/A N=40 Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes
End Stage Kidney Disease
Primary: Percent of Time in Range (TIR) Between 70-180 mg/dL — 80.4; 94.0 percentage of time
Early Phase 1 N=66 Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults
Neurosciences · Substance-Related Disorders · Behavior Problem
Primary: Alpha Learning Rate — .62; .43; .55; .21 Alpha Coefficient
Phase 4 N=101 Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
Metastatic Non Small Cell Lung Cancer
Primary: Number of Participants With All-Causality and Treatment-Related Treatment-Emergent Adverse Events (TEAEs) — 94; 16; 92; 7 Participants
Phase 2 N=230 Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
Chronic Hand Eczema
Primary: Cohort 1: Number of Participants With ≥1 Adverse Event (AE) — 1 Participants
Phase 2 N=91 Chemoprevention of Gastric Carcinogenesis
Gastric Cancer · Gastric Intestinal Metaplasia
Primary: The Difference in Cell DNA Damage, Based on Percent Positive Cells, Between Patients Treated With DFMO and Patients Treated With Placebo at 6 Months. — 5.07; 7.32…
Phase 2 N=28 Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia
COVID-19
Primary: Percentage of Patients Who Are Alive and Free From Advanced Respiratory Support Measures at Day 28. — 15; 8 Participants
N/A N=11,292 Outcomes After Hypotensive Neuraxial Anesthesia in Total Hip Arthroplasty
Total Hip Arthroplasty · Primary Total Hip Arthroplasty · Hypotension
Primary: Number of Participants Who Experience Myocardial Infarction, Cerebrovascular Accident, or Mortality — 16; 2; 0; 3 Participants
N/A N=32 Factors Affecting Early Progress of Cochlear Implant Outcomes in Adults
Sensorineural Hearing Loss, Bilateral
Primary: Score of the French MBAA2 Sentence Recognition Test in Quiet — 13; 19 Participants
Phase 2 N=376 Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) — 41.5; 45.3 Percentage of participants
Phase 1 N=52 A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Advanced Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants